Lifestance Health Group (LFST) 2026 Jefferies Healthcare Services and Technology Conference summary

Financial performance and guidance

• Revenue grew 26% year-over-year in Q2, with Adjusted EBITDA up 94%.

• Full-year revenue guidance was raised by $45 million in Q2, totaling a $70 million increase year-to-date.

• Adjusted EBITDA guidance increased by $15 million in Q2 and $30 million cumulatively.

• Long-term margin profile targets 15%-20% Adjusted EBITDA by 2028, with mid-teens revenue growth expected.

• Margin expansion is expected to come increasingly from operating leverage and technology investments.

Market opportunity and competitive positioning

• Operates in a behavioral health market with a total addressable market (TAM) over $50 billion.

• Current revenue represents low single-digit market penetration, with significant room for growth.

• Present in about half of the top 150 U.S. markets, with plans to deepen and expand geographic reach.

• Differentiators include national scale, hybrid care model (30% in-person, 70% virtual), and breadth of services.

• Focus on affordability through insurance acceptance and established payer relationships.

Specialty services and innovation

• Specialty revenue grew from $50 million last year to an expected $70 million this year, a 40% increase.

• Largest U.S. provider of neuropsychological testing, with growth driven by treatment-resistant depression solutions (TMS, Spravato).

• Specialty clinics are deployed efficiently within practice groups, leveraging existing infrastructure.

• Deliberate expansion pace: 32 TMS and 21 Spravato clinics as of midyear, with measured growth.

• Positioned to adopt new therapies, including psychedelics, as clinical and payer landscapes evolve.